Screener
Oruka Therapeutics, Inc. ORKA Paid-in-kind interest capitalized
Paid-in-kind interest capitalized at other companies
Other financials
Where this comes from
Reported directly by Oruka Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:PaidInKindInterest.
The source filing: Oruka Therapeutics, Inc.’s 10-K, filed March 12, 2026.
- Filed
- Mar 12, 2026, 4:03 PM EDT
- Fiscal year
- FY2025
- Accession
- 0001213900-26-026929
| Line item | Year Ended December 31, 2025 | Period from February 6, 2024 (inception) to December 31, 2024 |
|---|---|---|
| Adjustments to reconcile net loss to net cash used in operating activities: | ||
| Stock-based compensation expense | 24,240 | 14,919 |
| Net accretion of premiums and discounts on marketable securities | (5,003) | (2,245) |
| Non-cash interest expense | — | 1,468 |
| Non-cash lease expense | 458 | 127 |
| Depreciation expense | 83 | 27 |
| Changes in operating assets and liabilities: | ||
| Prepaid expenses and other current assets | (3,972) | (1,128) |
Item 8. Financial Statements and Supplementary
FAQ
- What is Oruka Therapeutics, Inc.'s paid-in-kind interest capitalized?
- Oruka Therapeutics, Inc. (ORKA) reported paid-in-kind interest capitalized of $1.47M in Q4 2024.
- What does paid-in-kind interest capitalized mean?
- Captures interest expense that is settled by issuing additional debt or equity instruments rather than through cash payments. This metric is critical for assessing the company's true leverage and cash flow obligations. It highlights instances where interest costs are deferred, potentially increasing the total debt burden over time.
Ask your AI about Oruka Therapeutics, Inc.'s paid-in-kind interest capitalized.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude